Hemispherx Lied About Immune Disorder Drug, Investor Says
A Hemispherx Biopharma Inc. shareholder hit the drugmaker and its executives with a derivative suit in Pennsylvania federal court Tuesday, accusing the company of lying about the safety and efficacy of...To view the full article, register now.
Already a subscriber? Click here to view full article